Clinical Trials Logo
  1. Home
  2. HCV Coinfection
  3. NCT01222611

HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir — FOSTER-C  

HCV Coinfection Clinical Trial

Official title:
Randomized, Controlled, Open Label, Pilot Study to Evaluate Fosamprenavir Activity on Genotype 1 Hepatitis C Virus (HCV) Infection Evolution in Human Immunodeficiency Virus (HIV) Co-infected Subjects With Antiretroviral Treatment Including Fosamprenavir

Clinical Trial Summary

This study examines the impact of fosamprenavir as part of an ART on virological, immunological and clinical parameters of genotype 1 HCV infection in HIV co-infected subjects. Fosamprenavir could have a direct or immune-mediated activity against HCV. If this is shown to be true, changes in HCV viral load or biological characteristics could be demonstrated.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01222611
Study type Interventional
Source Fundacion SEIMC-GESIDA
Contact
Status Completed
Phase Phase 4
Start date March 2011
Completion date June 2013
View Details
See also
  Status Clinical Trial Phase
Completed NCT02810275 - Folinic Acid: Supplementation and Therapy Phase 3
Completed NCT03145753 - Education vs Education Plus Intervention in HIV/HCV Diagnosis (DRIVE 03) N/A
Completed NCT01557998 - Testing and Linkage to Care for Injecting Drug Users in Kenya N/A
Completed NCT01335529 - Boceprevir in HIV-HCV Coinfected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin Phase 2
Completed NCT03499639 - Ombitasvir/ Paritaprevir / Ritonavir Plus Ribavirin in Management HCV and End-stage Kidney Disease Phase 4
Completed NCT03050905 - Proof of Concept Study To Evaluate the Efficacy and Justification Of OBV/PTV/r and DSV In Adults With Chronic Hepatitis C Virus Genotype 2K/1B Phase 4
Completed NCT02505243 - Evaluation of RIBAvirin Plasma COncentrations in Patients With Chronic Hepatitis C Infection Routinely Treated With Modern DAA Regimens
Recruiting NCT02086708 - Ultrasound Method to Measure Fibrosis of the Liver in Children N/A
Completed NCT03508115 - Changes in Cognition in HCV Patients After Virus Eradication With Direct Antiviral Agents
Completed NCT03214679 - Accessible HCV Care Intervention for People Who Inject Illicit Drugs (PWID) N/A
Completed NCT02938013 - deLIVER: Direct Acting Antiviral Effects on the Liver Phase 4
Completed NCT03549832 - Comparative Study of Two Regiemns in Management of Sofosbuvir/Daclatasvir Failure N/A
Completed NCT01900015 - Changes in Liver Steatosis After Switching to Raltegravir in HIV/HCV Coinfection Phase 4
Active, not recruiting NCT01529073 - Efficacy of Pegylated Interferon Plus Ribavirin Plus Nitazoxanide in HCV Genotype 4 and HIV Coinfection Phase 2
Recruiting NCT01747772 - Sonoelastography: Ultrasound Method to Measure Liver Fibrosis N/A
Completed NCT02693847 - Natural History of Liver Cirrhosis Diagnosed by Transient Elastography in HIV/HCV-coinfected Patients
Recruiting NCT03549312 - Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy Phase 4
Completed NCT03252483 - Integrating HIV and Hepatitis C Screening in an Urban Emergency Department N/A
Recruiting NCT03646396 - Effect of Sofosbuvir-daclatasuvir on Angiogenesis N/A
Completed NCT01335230 - The Study of Gut Associated Lymphocytes in HIV and HCV/HIV Co-infected Patients N/A